Endurance Part 2
Jul 16, 2026 - 00:15:12
Radio and PodcastLive Radio & Podcasts
Science & Medicine
Pivekimab sunirine
Pivekimab sunirine, a novel CD-123 antibody drug conjugate is approved for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Also, what the heck is BPDCN? Check out the Oncology Insights Newsletter:
About This Episode
Pivekimab sunirine is an episode from OncoPharm by OncoPharmPod. Pivekimab sunirine, a novel CD-123 antibody drug conjugate is approved for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Also, what the heck is BPDCN? Check out the On...
Podcast
This episode belongs to OncoPharm.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published May 28, 2026, 00:13:49 long, audio available.
Related Episodes
Continue listening to more episodes from OncoPharm.
A Decade of CAR-T, Ocra-T, & POLARGO
Jul 9, 2026 - 00:19:18
Breast Cancer Updates and T-Cell Stemness
Jun 25, 2026 - 00:19:23
Updates on capivasertib, belzutifan, talquetamab, & durvalumab
Jun 18, 2026 - 00:19:32
Asco '26
Jun 11, 2026 - 00:25:38
BCL2 & HER2 Targeting Agent Updates
May 21, 2026 - 00:13:45
IMHOTEP, PJP, and more
May 14, 2026 - 00:09:59
Vepdegestrant
May 7, 2026 - 00:11:35